Favorable safety outcomes of a perioperative propranolol and etodolac regimen in cancer patients in four randomized controlled trials

BackgroundThe perioperative use of the β-adrenergic blocker, propranolol, and/or the semi-selective COX-2 inhibitor, etodolac, has improved biomarkers of cancer metastasis in several small randomized controlled trials (RCTs). In colorectal cancer (CRC) patients, the combined regimen showed potential...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Nahida Sakis, Liat Sorski, Eden Asraf, Itay Ricon-Becker, Lee Shaashua, Rita Haldar, Bar Bruno Shvalbo, Maytal Shabat-Simon, Mordechai Gutman, Aviram Nissan, Ido Nachmany, Ilan Kent, Ron Pery, Niv Pencovich, Noam Shussman, Nir Wasserberg, Avraham Reshef, Elchanan Quint, Yifat Yosef Lishtzinsky, Hanoch Kashtan, Moshe Shabtai, Baruch Brenner, Eran Sharon, Tanir Allweis, Nitzan Shahar, Anabel Eckerling, Elad Sandbank, Oded Zmora, Shamgar Ben-Eliyahu
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2026-04-01
coleção:	Frontiers in Pharmacology
Assuntos:	COX2 inhibitors etodolac metastatic disease non-selective B-blockers perioperative care propranolol
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fphar.2026.1823113/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!